Literature DB >> 32162533

KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC.

Ashish M Kamat1, Neal Shore2, Noah Hahn3, Shaheen Alanee4, Hiroyuki Nishiyama5, Shahrokh Shariat6, Kijoeng Nam7, Ekta Kapadia8, Tara Frenkl8, Gary Steinberg9.   

Abstract

Background: Nonmuscle-invasive bladder cancer (NMIBC) is the most common form of bladder cancer, with high rates of disease recurrence and progression. Current treatment for high-risk NMIBC involves Bacillus Calmette-Guérin (BCG) therapy, but treatment options are limited for patients with recurrent or BCG-unresponsive disease. Aberrant programmed death 1 signaling has been implicated in BCG resistance and bladder cancer recurrence and progression, and pembrolizumab has shown efficacy in patients with BCG-unresponsive high-risk NMIBC. Aim: To describe the rationale and design for the randomized, comparator-controlled Phase III KEYNOTE-676 study, which will evaluate the efficacy and safety of pembrolizumab in combination with BCG in patients with persistent/recurrent high-risk NMIBC after BCG induction therapy. Trial registration number: NCT03711032.

Entities:  

Keywords:  Bacillus Calmette-Guérin; bladder cancer; immunotherapy; nonmuscle-invasive bladder cancer; pembrolizumab; programmed death 1; programmed death ligand 1

Mesh：

Substances：

Year:  2020        PMID： 32162533     DOI： 10.2217/fon-2019-0817

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  5 in total

1.  Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.

Authors:  Rafee Talukder; Dimitrios Makrakis; Leonidas N Diamantopoulos; Lucia Carril-Ajuria; Daniel Castellano; Ivan De Kouchkovsky; Vadim S Koshkin; Joseph J Park; Ajjai Alva; Mehmet A Bilen; Tyler F Stewart; Rana R McKay; Victor S Santos; Neeraj Agarwal; Jayanshu Jain; Yousef Zakharia; Rafael Morales-Barrera; Michael E Devitt; Michael Grant; Mark P Lythgoe; David J Pinato; Ariel Nelson; Christopher J Hoimes; Evan Shreck; Benjamin A Gartrell; Alex Sankin; Abhishek Tripathi; Roubini Zakopoulou; Aristotelis Bamias; Jure Murgic; Ana Fröbe; Alejo Rodriguez-Vida; Alexandra Drakaki; Sandy Liu; Vivek Kumar; Giuseppe Di Lorenzo; Monika Joshi; Pedro Isaacsson Velho; Lucia Alonso Buznego; Ignacio Duran; Marcus Moses; Pedro Barata; Guru Sonpavde; Evan Y Yu; Jonathan L Wright; Petros Grivas; Ali Raza Khaki
Journal:  Clin Genitourin Cancer       Date:  2021-12-17       Impact factor: 2.872

Review 2.  Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics.

Authors:  Julianne D Twomey; Baolin Zhang
Journal:  AAPS J       Date:  2021-03-07       Impact factor: 4.009

3.  Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin in the Veterans Affairs Health System.

Authors:  Stephen B Williams; Lauren E Howard; Meagan L Foster; Zachary Klaassen; Jan Sieluk; Amanda M De Hoedt; Stephen J Freedland
Journal:  JAMA Netw Open       Date:  2021-03-01

4.  Clinical Value Analysis of Xiaozheng Decoction Combined with Bladder Perfusion for Postoperative Treatment of Bladder Cancer and Its Effect on Serum miR-143 and miR-92a.

Authors:  Xifeng Yang; Honghong Lv; Wenjing Jiang; Jinzhi Zhang; Hong Hua
Journal:  J Healthc Eng       Date:  2022-03-24       Impact factor: 2.682

5.  Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex.

Authors:  Antonín Brisuda; James C S Ho; Pancham S Kandiyal; Justin T-Y Ng; Ines Ambite; Daniel S C Butler; Jaromir Háček; Murphy Lam Yim Wan; Thi Hien Tran; Aftab Nadeem; Tuan Hiep Tran; Anna Hastings; Petter Storm; Daniel L Fortunati; Parisa Esmaeili; Hana Novotna; Jakub Horňák; Y G Mu; K H Mok; Marek Babjuk; Catharina Svanborg
Journal:  Nat Commun       Date:  2021-06-08       Impact factor: 14.919
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.